Composition (%) | ΔDi-0S | ΔDi-UA2S | ΔDi-6S | ΔDi-4S | ΔDi-diSD | ΔDi-diS | ΔDi-diSE | ΔDi-triS |
|---|
CVC-cont-1 | n.d. | 8.5 | 84.3 | 7.2 | n.d. | n.d. | n.d. | n.d. |
CVC-1 | n.d. | 10.3 | 43.9 | 45.2 | 0.22 | 0.08 | 0.3 | n.d. |
CVC-cont-2 | n.d. | 7 | 90 | 3 | n.d. | n.d. | n.d. | n.d. |
CVC-2 | n.d. | 17.3 | 16.2 | 66 | 0.09 | 0.02 | 0.39 | n.d. |
CVC-cont-3 | n.d. | 8.1 | 84.9 | 7 | n.d. | n.d. | n.d. | n.d. |
CVC-3 | n.d. | 24.1 | 22.9 | 52.2 | 0.12 | 0.03 | 0.65 | n.d. |
- *CS = chondroitin sulphate; DS = dermatan sulphate; CVC = cerebrovascular cells; cont = control; CVC-1, CVC-2, CVC-3 = chloroquine-treated; n.d. = not detected
- DDi-0S: 2-acetamido-2-deoxy-3-O-(b-D-xylo-hex-4-enopyranosyluronic acid)-D-galactose
- DDi-4S: 2-acetamido-2-deoxy-4-O-sulphosulpho-3-O-(b-D-xylo-hex-4-enopyranosyluronic acid)-D-galactose
- DDi-6S: 2-acetamido-2-deoxy-6-O-sulpho-3-O-(b-D-xylo-hex-4-enopyranosyluronic acid)-D-galactose
- DDi-UA2S: 2-acetamido-2-deoxy-3-O-(2-O-sulpho-b-D-xylo-hex-4-enopyranosyluronic acid)-D-galactose
- DDi-diSB: 2-acetamido-2-deoxy-4-O-sulpho-3-O-(2-O-sulpho-b-D-xylo-hex-4-enopyranosyluronicacid)-D-galactose
- DDi-diSD: 2-acetamido-2-deoxy-6-O-sulpho-3-O-(2-O-sulpho-b-D-xylo-hex-4-enopyranosyluronicacid)-D-galactose
- DDi-diSE: 2-acetamido-2-deoxy-4,6-di-O-sulpho-3-O-(b-D-xylo-hex-4-enopyranosyluronic acid)-D-galactose
- DDi-triS: 2-acetamido-2-deoxy-4,6-di-O-sulpho-3-O-(2-O-sulpho-b-D-xylo-hex-4-enopyranosyluronic acid)-D-galactose acid)-D-galactose
